Received Oct 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | — |
Covid-19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Covid-19) in a 73-year-old female patient who received mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) for COVID-19 prophylaxis. Previously administered products included for COVID-19 prophylaxis: Spilevax in October 2023, Moderna COVID-19 (2nd dose, Batch Number :028A21A), Moderna COVID-19 (1st dose and Batch Number :002A21A). Past adverse reactions to the above products included No adverse effect with Moderna COVID-19, Moderna COVID-19 and Spilevax. Concurrent medical conditions included Asthma. In September 2024, the patient received dose of mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (unknown route) 1 dosage form. In August 2025, the patient experienced COVID-19 (Covid-19). At the time of the report, COVID-19 (Covid-19) outcome was unknown. No concomitant medications provided by the reporter. It was reported that patient received Moderna COVID-19 vaccines since the start of the vaccination. The patient had no information for her 3rd and 4th doses except the date of the administration. The patient received a vaccination dose as Spikevax on Oct-2023, and the patient received a dose on Sep-2024 as Moderna Vaccine. No treatment medications provided by the reporter.
Asthma